INTRODUCTION
H ypertension is the leading risk factor for early mortality worldwide and accounts for nearly 10% of all disability adjusted life years [1] . A disproportionate burden of hypertension and hypertensionrelated diseases occur in low and middle-income countries (LMICs) [2] . In addition to traditional risk factors such as age and obesity, inflammation is increasingly accepted as an important factor in the pathophysiology of hypertension [3, 4] . Infections such as HIV that induce chronic inflammation may increase hypertension risk and may provide insight into the relationship between chronic inflammation and hypertension [5] .
Little is known about the predictors and outcomes of hypertension in HIV-infected adults. Recent retrospective and cross-sectional studies have confirmed that the prevalence of hypertension is higher in HIV-infected adults than their uninfected counterparts [6] [7] [8] . Cohort studies of HIVinfected adults from several HIC and LMICs have reported a high incidence of hypertension [9] [10] [11] [12] . To our knowledge, no prospective data have yet been published describing the relationship between hypertension, ART initiation, HIVrelated inflammation and mortality in HIV-infected adults.
We therefore analysed blood pressure and mortality data from a prospective cohort of HIV-infected Haitian adults. Our primary objective was to determine whether high blood pressure is an independent predictor of mortality in HIV-infected adults. Secondary objectives were to determine the incidence rate of hypertension in adults started on either early or delayed antiretroviral therapy (ART) and to determine whether inflammatory biomarkers can predict incident hypertension in HIV-infected adults.
MATERIALS AND METHODS

Study design
Our study followed individuals enrolled in the CIPRA HT-001 trial [13] . CIPRA HT-001 was a randomized controlled study conducted at the GHESKIO Center in Port-au-Prince, Haiti. Eligibility was limited to HIV-infected, ART-naive, nonpregnant adults with CD4 þ T cells between 200 and 350 cells/ml and no history of AIDS-defining conditions. Between August 2005 and July 2008, 816 participants were enrolled and underwent 1 : 1 randomization to either early or delayed ART initiation. Participants in the early group started treatment within 2 weeks of randomization. Participants in the delayed group started treatment when their CD4 þ T cells fell below 200 cells/ml or with the development of an AIDS-defining condition. All participants provided informed consent. The study was approved by the Institutional Review Boards at both GHESKIO and Weill Cornell Medicine.
The CIPRA HT-001 trial officially ended in June 2009 when a scheduled interim analysis showed the hazard ratio for mortality to be 4.0 (P < 0.01) in the delayed group. This prompted the Data Safety and Monitoring Board to recommend that all participants who had not met study criteria for initiating ART start treatment immediately with continued follow-up [13] . After the end of the CIPRA HT-001 trial, we continued to follow all study participants through June 2016 to determine the incidence of hypertension.
Study methods
A study clinician saw participants in both groups at enrolment, monthly for the first 3 months after enrolment, and subsequently every 3 months. At each study visit, a research nurse documented vital signs, including blood pressure. Blood pressure measurement was performed after at least 5 min of sitting using a mercury sphygmomanometer. If the first blood pressure measurement was elevated, a second blood pressure measurement was taken after at least 15 min and the average of these two measurements was recorded.
Prevalent and incident hypertension were defined using the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure Report (JNC-7) [14] . Prevalent hypertension was defined as receiving medication for hypertension at the time of enrolment and/or SBP at least 140 mmHg and/or DBP at least 90 mmHg during both of the first two study visits. Incident hypertension was defined as having two blood pressure readings at least 140/ 90 mmHg or starting medication for hypertension (among study participants who did not have prevalent hypertension). In addition to classifying prevalent hypertension and incident hypertension, we also categorized the enrolment SBP as high enrolment SBP (enrolment SBP >140 mmHg), normal enrolment SBP (enrolment SBP 90-140 mmHg) or low enrolment SBP (enrolment SBP <90 mmHg). Treatment for hypertension was provided according to Haitian national guidelines, which are in line with the JNC-7 guidelines; thiazide diuretics were given as first-line therapy for most patients with hypertension.
For all participants starting ART, a first-line regimen of lamivudine (150 mg every 12 h) and zidovudine (300 mg every 12 h) in a fixed-dose combination, and efavirenz (600 mg daily, or 800 mg daily if participants were also taking rifampin for treatment of comorbid tuberculosis) was given. Drug substitutions were made according to the WHO guidelines [15] .
For study participants who missed a study visit, a field worker employed by GHESKIO visited the home of the patient. A study participant was only declared 'lost to follow-up' if they could not be found after three home-visit attempts over a 6-month period. Death was documented by one of the following: obituary, autopsy report, hospital death certificate or a field worker report documenting verbal communication with individual's healthcare provider or family member.
Laboratory measurements
CD4
þ T-cell counts, HIV-1 RNA levels and serum creatinine were measured on-site at GHESKIO. CD4 þ T-cell counts (Becton Dickinson and Company, Franklin Lakes, New Jersey, USA) were performed at enrolment. HIV-1 RNA levels were measured from banked plasma specimens collected at enrolment using the NucliSens EasyQ HIV-1 PCR Test, v1.2 (BioMérieux, Lyon, France). The lower limit of detection for HIV-1 RNA was 50 copies/ml or less. Serum creatinine was measured before ART initiation and estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [16] .
The plasma concentrations of C-reactive protein (CRP), IL-6 and D-dimer were measured from banked plasma specimens collected at enrolment and stored at -808C. Biomarker analysis was performed in the Core Laboratory of the Clinical and Translational Science Center of Weill Cornell Medicine. All assays were performed in duplicate. CRP and IL-6 were measured using the V-PLEX human CRP and V-PLEX human IL-6 kit, respectively, from Meso Scale Discovery (Gaithersburg, Maryland, USA) following the manufacturer's instructions. The intra-assay variation, inter-assay variation and measurable ranges for CRP and IL-6 were 4.1 and 4.5%, 10.5 and 7.3%, 14-216 500 and 0.18-749 pg/ml, respectively. D-dimer was measured using IMUCLONE D-dimer ELISA kit (Sekisui Diagnostics LLC, Stamford, Connecticut, USA) following the manufacturer's protocol. The intra-assay variation, inter-assay variation and measurable range were 3.6, 11.7 and 4.88-195 ng/ml, respectively.
Statistical analysis
Clinical and laboratory information were entered electronically in Haiti and managed by the Frontier Science and Technology Research Foundation (Amherst, New York, USA). Data were exported into Microsoft Excel for cleaning, and analysis was performed using Stata 14 software (StataCorp LP, San Antonio, Texas, USA). All analyses were based on intention to treat. Categorical variables were described as proportions (percentages). Continuous variables were described as medians (interquartile ranges, IQRs).
Prevalence of hypertension was measured as the proportion of participants in both study arms with hypertension at the time of study enrolment among all participants. The incidence proportion, or cumulative incidence, reflects the number of new diagnoses of hypertension among the population at risk during the study period. Differences in incidence proportion between the early and delayed ART groups were evaluated using two-sample proportions test. The incidence rate was calculated as the number of new diagnoses of hypertension per 100 person-years of followup. The two-sample incidence rate comparison is based on the log-rank test. The probability of hypertension-free survival was calculated using standard Kaplan-Meier survival methods and the log-rank test. Participants who were lost during the trial were censored at the time of their last clinic visit, and participants who died were censored on their date of death.
Plots of CRP, IL-6 and D-dimer revealed skewed data and were log transformed to approximate a normal distribution. Cox proportional hazard models using time-independent variables (sex and group assignment) and enrolment values of time-dependent variables (age, HIV Clinical Stage, BMI, SBP and DBP creatinine, eGFR, CRP, IL-6, D-dimer, CD4 þ T-cell count and HIV-1 RNA level) were used to calculate the hazard ratios for the primary endpoint, incident hypertension. Cox proportional hazard models were used to identify factors associated with incident hypertension. Variables in the Cox models were chosen by backward selection procedure with exit criteria of P value more than 0.05. The same final model was selected by forward selection procedure with entry criteria of P value less than 0.05. All hazard ratios are reported with a 95% confidence interval (95% CI). Only P values less than 0.05 were considered statistically significant.
RESULTS
Study population
For participation in the original CIPRA HT-001 trial, 1066 individuals were screened and 816 participants were enrolled. In the early group, all 408 participants started ART immediately after enrollment; in the delayed group, 355 of 408 (87.0%) participants started ART after a median delay of 1.3 years [13] . [13, 17] . There were no statistically significant differences in the log-normalized values of HIV-1 RNA, CRP, IL-6 or D-dimer at enrolment between the early and delayed groups.
Participants were followed for a median of 7.3 years (IQR: 5.0-8.3). There were 82 deaths (N ¼ 31, early group; N ¼ 51, delayed group) and 244 lost (N ¼ 123, early group; N ¼ 121, late group) over the 11-year study period from the beginning of enrolment in 2005 through the end of followup in 2016. Table 2 describes the prevalence and incidence of hypertension in whole cohort (all participants) as well as in the two study groups (early group vs. delayed group). Only 5.3% (43/816) of participants had prevalent hypertension at the time of study enrolment (N ¼ 20, early group vs. N ¼ 23, delayed group). The prevalence rate of hypertension in the whole cohort was 5.3% (CI: 3.7-6.8%) and was similar in the early and delayed groups new diagnosis of hypertension were also similar in the early and delayed groups (see Table S1 ). Figure 1a displays the probability of hypertension-free survival for the cohort, which was 70% at 8 years. Figure 1b illustrates that the trends in hypertension-free survival were similar in the early and delayed groups (P ¼ 0.58 by logrank test). Table 3 summarizes both the unadjusted and adjusted predictors of incident hypertension at enrolment. In multivariate analyses, the four independent predictors of incident hypertension were older age [adjusted hazard ratio (aHR) ¼ 1.32 per decade, P ¼ 0.002], higher BMI (aHR ¼ 1.07 per 1 unit increase in BMI, P < 0.001), higher SBP (aHR ¼ 2.02 per 10 mmHg increase in SBP, P < 0.001) and higher IL-6 level (aHR 1.24 per log 2 increase, P < 0.001). The same final multivariate model was reached with both forward and backward selection procedures.
Hypertension outcomes
Predictors of incident hypertension
Blood pressure and mortality
Blood pressure was an independent predictor of mortality by multiple measures, including prevalent hypertension, prevalent hypertension or early incident hypertension (within the first year of study enrolment) and baseline SBP. These associations remained statistically significant after adjusting for age and sex. Additional controlling for other factors such as randomization group, HIV clinical stage and CD4 þ T-cell count lead to similar results. These data are displayed in Table 4 .
Of all of the measures of blood pressure, the participant's SBP at enrolment was the strongest predictor of mortality. Kaplan-Meier curves for the relationship between enrolment SBP and mortality are displayed in Fig. 2 . We also performed multivariate Cox regression analysis to confirm these results.
Participants with high SBP (>140 mmHg) at enrolment had higher mortality when compared with individuals with normal SBP (90-140 mmHg) (hazard ratio 3.03; CI: 1.39-6.61, P ¼ 0.005). This association remained statistically significant after adjusting for age and sex (aHR ¼ 2.47; CI: 1.10-5.57, P ¼ 0.03), and was still significant after controlling for other factors such as randomization group, HIV clinical stage and CD4 þ T-cell count.
Participants with low SBP (<90 mmHg) at enrolment also had increased mortality risk when compared with individuals with normal SBP (90-140 mmHg) . This relationship remained statistically significant after adjusting for age and sex in a Cox regression model (aHR 2.25; CI: 1.03-4.95, P ¼ 0.042).
DISCUSSION
In our study, HIV-infected adults with hypertension at enrolment had a more than two-fold higher risk of mortality. Independent predictors of incident hypertension included traditional risk factors (age and adiposity) and HIV-related inflammation (plasma IL-6).
Our study provides the first prospective evidence that high blood pressure is an important determinant of longterm survival in HIV-infected adults. In our study, both prevalent hypertension and early incident hypertension were associated with increased mortality during the 10-year study period. These results confirm the hypothesis generated from a retrospective analysis of electronic medical records for HIV-infected adults in Kenya between 2005 and 2010 [18] . In that study, a high SBP measurement recorded in an electronic medical record was associated with increased mortality in HIV-infected men with WHO clinical stage 1 or 2 disease. On the basis of these findings, HIV clinics in LMIC should ensure that blood pressure is measured regularly and accurately in order to accomplish early diagnosis and early treatment for hypertension [19] . Both high and low SBP at enrolment was also associated with higher mortality in our study population. HIV-infected adults with a SBP of less than 90 mmHg at study enrolment had a two-fold higher mortality than participants with normal SBP. Low SBP has previously been reported as a strong predictor of mortality in HIV-infected adults in Kenya, particularly those with advanced HIV disease (WHO clinical stage 3 or 4) [18] . The relationship between low blood pressure and mortality is possibly due to adrenal insufficiency, autonomic dysfunction, concomitant infections or bacterial translocation [18] . Both high and low SBP, therefore, may be helpful in identifying HIV-infected patients who would benefit from differentiated models of care with tailored services to reduce their risk of mortality [20] . The WHO has recommended that, 'differentiated care for HIV requires delivery of different care packages for people based on their needs', but current models of differentiated care have started with widely available markers of HIV disease severity such as CD4 þ T-cell count or WHO clinical stage. SBP may be an additional, simple, widely available biomarker indicating the need for new differentiated care pathways.
Our study is the first to report that HIV-related inflammation (elevated plasma IL-6) precedes and predicts incident hypertension in HIV-infected adults. IL-6 levels are commonly elevated in HIV-infected adults due to dysregulation of T cells [5] . In fact, because the enrolment IL-6 levels were high in our cohort, our finding may underestimate the predictive role of elevated IL-6 for incident hypertension in HIV-infected adults. In HIV-uninfected adults, two studies have reported an association between IL-6 levels and incident hypertension [21, 22] . In addition, lowering blood pressure in HIV-uninfected adults has been shown to reduce IL-6 levels [23] . One smaller case-control study of HIV-infected adults in Uganda demonstrated a trend towards higher IL-6 predicting incident hypertension, but the results were not statistically significant [24] . The relationship between IL-6 and hypertension in HIV-infected adults may be important for two reasons. First, the IL-6 pathway may provide targets for interventions to prevent hypertension [4] . Second, hypertension could be a modifiable mediator in the relationship between higher IL-6 levels and higher rates of cardiovascular events [25] . Additional prospective cohort studies are needed to determine the relationship between IL-6, hypertension and cardiovascular disease and to compare between HIV-infected and HIVuninfected populations.
In our cohort of HIV-infected Haitian adults, the incidence of hypertension was 3.41 per 100 person-years and over 20% of participants were diagnosed with hypertension by 8 years. This hypertension incidence rate is nearly twice the incidence rate that has been reported in HIV-uninfected adults of similar age in the United States [26] [27] [28] . This finding is particularly striking because, at enrolment, our study participants had relatively low blood pressure and BMI. As expected from the observation of premature ageing in HIV-infected adults, the hypertension incidence rates in our cohort are similar to the incidence rates reported for adults 10-20 years older than the individuals in our cohort [26] [27] [28] [29] . Two other longitudinal studies from Africa have also reported similarly high incidence rates of hypertension in cohorts of HIV-infected adults [9, 10] . These findings are particularly concerning because HIV-infected adults with hypertension are at even higher risk of hypertensionrelated complications than HIV-uninfected adults with similar blood pressures [30] . Therefore, HIV clinicians in LMIC must be better equipped to diagnose and treat hypertension [31] .
One limitation of our study is that 244 study participants were lost to follow-up during the course of our 10-year study (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . We do not think that this had a major impact on our findings, though, for several reasons. First, the average lost to follow-up rate was only nearly 3% per year. Second, the average follow-up time contributed by participants who were lost was still 4.6 years (IQR: 1.8-6.2 years). If participants developed incident hypertension prior to being lost, the time from enrolment to incident hypertension was considered their person time at risk. If participants did not develop hypertension prior to being lost, the time from enrolment to last known date alive was considered as their person time at risk. Third, baseline characteristics among study participants who were lost and participants who completed the study were similar. Another limitation of the current study is that some additional risk factors for mortality, such as dyslipidaemia, type 2 diabetes mellitus, serum uric acid and lipodystophy, were not considered. Future studies should include these risk factors.
In conclusion, hypertension incidence is high in HIVinfected adults in Haiti. Both high and low SBP at enrolment are associated with higher mortality. SBP may be useful biomarkers in identifying patients who need differentiated care to reduce mortality. Higher enrolment IL-6 is associated with an increased risk of incident hypertension. Further research is needed to determine the mechanism for how IL-6 leads to hypertension in HIV-infected adults and to explore prevention strategies that target the IL-6 pathway.
Reviewers' Summary Evaluations
Referee 1
The authors have studied incidence of hypertension and its predictive power for mortality in a large group of HIVinfected adults. Despite the relatively young age, the low mean levels of base-line blood pressure and of body mass index, incidence of hypertension was substantial in a 7-year follow-up period. Both prevalent and incident hypertension were highly predictive of future mortality. A relevant feature of this study is the strong association of interleukin-6 with hypertension, whose interpretation is still uncertain owing to the overall high levels of this indicator of inflammation in the HIV-infected patients. This calls for further investigation in both HIV-infected and noninfected subjects.
Referee 2
The methodology applied to the data is overall correct; the results are reliable and adequately discussed. Moreover, the reported data are relatively new and obtained by a relatively large cohort of patients. The main limitation of this study is that the authors did not consider among predictors of mortality some risk factors strongly associated with HAART such as dyslipidemia and type 2 diabetes. In addition, other factors, such as renal function, serum uric acid or lipodystrophy, have not been considered.
